Canada markets open in 1 hour 32 minutes

NLS Pharmaceutics AG (NLSP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6400-0.3600 (-18.00%)
At close: 04:00PM EST
1.6200 -0.02 (-1.22%)
Pre-Market: 07:23AM EST

NLS Pharmaceutics AG

Alter Postplatz 2
Stans 6370
41 41 618 80 00

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Alexander Zwyer M.B.A.Pres, CEO & DirectorN/AN/A1969
Mr. Subhasis Roy M.B.A.Interim Chief Financial OfficerN/AN/A1969
Dr. Silvia PanigoneChief Operating OfficerN/AN/A1972
Mr. Eric Konofal M.D., Ph.D.Chief Scientific OfficerN/AN/A1967
Dr. Christian C. Wenger Dr. iur., L.L.M., LL.M., Ph.D.Gen. CounselN/AN/A1964
Ms. Sharon KeysHead of Regulatory AffairsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland.

Corporate Governance

NLS Pharmaceutics AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.